NCT07712094尚未招募2 期
A Prospective, Parallel, Double-cohort, Multicenter Phase II Clinical Study of Ivonescimab (AK112) Combined With IP Chemotherapy ± TACE for First-line Treatment of Metastatic Digestive System Neuroendocrine Cancer
Tianjin Medical University Cancer Institute and Hospital8 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2026年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 56
- 试验地点
- 8
- 主要终点
- progression-free survival (PFS)
研究概览
简要总结
This study is a single prospective, parallel, double-cohort, multicenter phase II clinical trial, aiming to evaluate the efficacy and safety of ivonescimab (AK112) combined with IP chemotherapy ± TACE in the first-line treatment of metastatic digestive system neuroendocrine cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 - 75 years old;
- •Metastatic digestive system neuroendocrine carcinoma (NEC) confirmed by tissue or cytological examination;
- •For cohort 2 only: Liver metastasis, suitable for TACE;
- •No previous systemic treatment; For patients who received adjuvant therapy, disease recurrence and metastasis more than 6 months after the last treatment can be regarded as first-line treatment;
- •Clear measurable lesions meeting the requirements of RECIST (1.1); If the lesion that received previous local treatment (radiation, ablation, vascular intervention, etc.) is the only lesion, there must be clear imaging evidence of disease progression for this lesion;
- •ECOG score of 0 or 1;
- •Expected survival ≥ 12 weeks;
- •Basic normal functions of major organs and bone marrow;
- •Male or female patients with reproductive capacity voluntarily use effective contraceptive methods during the study period and within 6 months after the last study medication, such as double barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered to have reproductive capacity, unless the female patient has naturally menopause, artificial menopause or sterilization (such as hysterectomy, bilateral ovary removal or radiotherapy of the ovaries, etc.).
- •Have fully understood this study, voluntarily participated, and signed the informed consent form.
排除标准
- •Within the past 5 years, have been diagnosed with other malignant tumors (excluding carcinoma in situ, basal cell carcinoma, etc.);
- •Known to be allergic to any component of any study drug; have a history of severe hypersensitivity reaction to other monoclonal antibodies;
- •Within 4 weeks before enrollment, have received approved or investigational systemic anti-tumor treatment, including: photodynamic therapy, chemotherapy, radical radiotherapy, ablation, local radiotherapy (allowing for palliative radiotherapy for bone metastases at least 2 weeks before the study drug treatment), biological immunotherapy, targeted therapy, etc.;
- •Within 4 weeks before enrollment, have participated in other domestic clinical trials of drugs that have not been approved or are not yet on the market and have received corresponding trial drug treatment;
- •Within 4 weeks before enrollment, have received any surgery or invasive treatment or operation (except for intravenous catheterization, puncture drainage, etc.);
- •The patient currently has active ulcers in the stomach and duodenum, ulcerative colitis and other digestive tract diseases or active bleeding from the unresected tumor, or conditions that the investigator deems may cause gastrointestinal bleeding or perforation;
- •Within 3 months before enrollment, have obvious evidence or history of bleeding (more than 30 mL of bleeding within 3 months, hematemesis, black stool, bloody stool), hemoptysis (more than 5 mL of fresh blood within 4 weeks), or have had a thromboembolic event within 12 months (including stroke events and/or transient ischemic attacks);
- •Have significant clinical cardiovascular diseases, including but not limited to acute myocardial infarction within 6 months before enrollment, severe/unstable angina pectoris or coronary artery bypass surgery; New York Heart Association (NYHA) class > 2 for congestive heart failure; Drug treatment for ventricular arrhythmias; Electrocardiogram (ECG) showing QTc interval ≥ 480 milliseconds;
- •Unstable brain parenchymal metastases, spinal cord metastases or compression, cancerous meningitis or meningitis metastasis;
- •Have third space fluid that cannot be controlled by drainage methods (such as large amounts of ascites, pleural effusion, pericardial effusion, etc.), and the subjects need to control the third space fluid through drainage within 14 days before administration;
- •Active or uncontrolled severe infection (≥ CTCAE grade 2 infection);
- •Known human immunodeficiency virus (HIV) infection; Known significant liver disease history, including viral hepatitis [must exclude active HBV infection if the HBV DNA is positive (> 1×10^4 copies/mL or > 2000 IU/ml); known hepatitis C infection (HCV) and HCV RNA positive (> 1×10^3 copies/mL), or other hepatitis, liver cirrhosis];
- •Known mental illness, drug abuse, alcoholism or drug addiction history.
- •Pregnant or lactating women.
- •Have any disease, treatment, laboratory test abnormalities in the past or currently, which may confuse the research results, affect the full participation of the subjects in the research, or the participation in the research may not be in the best interests of the subjects.
- •Local or systemic diseases not caused by malignant tumors, or secondary diseases or symptoms of tumors, which may lead to higher medical risks and/or uncertainty in survival period evaluation, such as tumor leukemia reaction (white blood cell count > 20×109/L), cachexia manifestations (such as weight loss of more than 10% within 3 months before screening), etc.
- •Patients judged by the investigator to be unsuitable to participate in this study.
结局指标
主要结局
progression-free survival (PFS)
时间窗: Up to 2 years
PFS is defined as the time from date of treatment start to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1
次要结局
- objective response rate (ORR)(Up to 2 years)
- disease control rate (DCR)(Up to 2 years)
- duration of response (DOR)(Up to 2 years)
- overall survival (OS)(Up to 2 years)
- The number of subjects experiencing adverse events (AEs)(From the time of treatment start through 90 days following termination of treatment with investigational product)
研究者
研究点 (8)
Loading locations...
相似试验
招募中
不适用
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast CancerNCT07285382wanghaibo120
招募中
2 期
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary AldosteronismPrimary AldosteronismNCT07470983Shandong Suncadia Medicine Co., Ltd.60
招募中
1 期
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid TumorsEsophageal and/or Cardia CancerUrothelial Carcinoma (UC)MelanomaNCT07518043Shanghai Henlius Biotech174
进行中（未招募）
3 期
Clinical trial of Cenobamate tablets in Focal SeizuresCTRI/2025/09/094091Bajaj Healthcare Limited230
招募中
3 期
Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular EdemaRetinal Vein Occlusion With Macular EdemaNCT07708142SANGMYUNG innovation312